|
Neurotech International Limited is a clinical-stage biopharmaceutical development company focused predominantly on paediatric neurological disorders. The company develops and commercialises a broad-spectrum oral cannabinoid drug therapy called NTI164, which is intended to be regulated as a prescription-only drug. Its pipeline targets conditions including Autism Spectrum Disorder (ASD), Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS), Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), Rett Syndrome, and spastic cerebral palsy. Neurotech has completed Phase II/III trials in ASD and Phase I/II trials in PANDAS/PANS and Rett Syndrome, and has received clearance for a Phase III study in ASD and a Phase I/II trial in spastic cerebral palsy. The company holds an exclusive worldwide licence for its lead candidate and has completed extensive preclinical studies demonstrating potent anti-neuroinflammatory effects. Summarised from the company's own disclosures, fiscal year ended Jun 2026 |
Industry Health Care Equipment & Services | Homepage neurotechinternational.com |
| Sector Healthcare | IR page neurotechinternational.com/investor-dashboard | |
|
Tags
paediatric neurology, cannabinoid therapy, autism spectrum disorder, pandemic, clinical trials, oral drug therapy, NTI164
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | A$ 27.473M |
| P/E | -4.20 |
| P/BV | 27.08 |
| P/S | — |
| P/OCF | -6.50 |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | -366.7% |
| ROI | -1,069.9% |
| ROIC | -1,069.9% |
| Profit margin | — |
| Growth | |
|---|---|
| Revenue growing | No |
| Profits growing | No |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | Yes |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 0 |
| Quality score | -80.0% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpPrompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.